3/27
08:04 pm
coya
Wall Street Analysts Think Coya Therapeutics, Inc. (COYA) Could Surge 149.62%: Read This Before Placing a Bet [Yahoo! Finance]
Medium
Report
Wall Street Analysts Think Coya Therapeutics, Inc. (COYA) Could Surge 149.62%: Read This Before Placing a Bet [Yahoo! Finance]
3/27
08:15 am
coya
Coya Therapeutics, Inc. (NASDAQ: COYA) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $18.00 price target on the stock.
Medium
Report
Coya Therapeutics, Inc. (NASDAQ: COYA) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $18.00 price target on the stock.
3/26
08:15 am
coya
Coya Therapeutics Reports Progress from an Academic Supported First-in-Class Treg-derived Exosome Program
Neutral
Report
Coya Therapeutics Reports Progress from an Academic Supported First-in-Class Treg-derived Exosome Program
3/20
08:05 am
coya
Coya Therapeutics, Inc. (NASDAQ: COYA) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $14.00 price target on the stock.
Medium
Report
Coya Therapeutics, Inc. (NASDAQ: COYA) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $14.00 price target on the stock.
3/19
09:18 am
coya
Exosome Therapeutics Market Report 2025: 120+ Drug Candidates in Pipeline, Market to Reach $1.4 Billion by 2040, Growing at 41.1% CAGR [Yahoo! Finance]
Low
Report
Exosome Therapeutics Market Report 2025: 120+ Drug Candidates in Pipeline, Market to Reach $1.4 Billion by 2040, Growing at 41.1% CAGR [Yahoo! Finance]
3/18
09:44 am
coya
Coya Therapeutics, Inc. (NASDAQ: COYA) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $18.00 price target on the stock.
Medium
Report
Coya Therapeutics, Inc. (NASDAQ: COYA) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $18.00 price target on the stock.
3/18
08:15 am
coya
Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2024 Financial Results
Medium
Report
Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2024 Financial Results
3/10
08:58 am
coya
Coya Therapeutics, Inc. (NASDAQ: COYA) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $15.00 price target on the stock.
High
Report
Coya Therapeutics, Inc. (NASDAQ: COYA) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $15.00 price target on the stock.
2/25
08:15 am
coya
Coya Therapeutics to Participate in KOL Call Hosted by BTIG to Discuss the Potential Treatment of Alzheimer’s Disease Using GLP-1 Agonists and Combinations
Medium
Report
Coya Therapeutics to Participate in KOL Call Hosted by BTIG to Discuss the Potential Treatment of Alzheimer’s Disease Using GLP-1 Agonists and Combinations
2/7
03:23 am
coya
Coya Therapeutics' Alzheimer's Candidate Shows Improved Inflammatory Blood Markers Following Monthly Dosing [Yahoo! Finance]
Medium
Report
Coya Therapeutics' Alzheimer's Candidate Shows Improved Inflammatory Blood Markers Following Monthly Dosing [Yahoo! Finance]
2/6
06:07 pm
coya
Coya Therapeutics, Inc. (NASDAQ: COYA) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $14.00 price target on the stock.
Low
Report
Coya Therapeutics, Inc. (NASDAQ: COYA) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $14.00 price target on the stock.
2/6
09:04 am
coya
Coya Therapeutics, Inc. (NASDAQ: COYA) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $15.00 price target on the stock.
Low
Report
Coya Therapeutics, Inc. (NASDAQ: COYA) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $15.00 price target on the stock.
2/6
08:22 am
coya
Coya Therapeutics Reports Statistically Significant Improvement of Inflammatory Blood Markers in Patients with Alzheimer's Disease Following Monthly Dosing with Low-Dose IL-2, Further Supporting Clinical Development [Yahoo! Finance]
Low
Report
Coya Therapeutics Reports Statistically Significant Improvement of Inflammatory Blood Markers in Patients with Alzheimer's Disease Following Monthly Dosing with Low-Dose IL-2, Further Supporting Clinical Development [Yahoo! Finance]
2/6
08:00 am
coya
Coya Therapeutics Reports Statistically Significant Improvement of Inflammatory Blood Markers in Patients with Alzheimer’s Disease Following Monthly Dosing with Low-Dose IL-2, Further Supporting Clinical Development
Medium
Report
Coya Therapeutics Reports Statistically Significant Improvement of Inflammatory Blood Markers in Patients with Alzheimer’s Disease Following Monthly Dosing with Low-Dose IL-2, Further Supporting Clinical Development
2/4
08:15 am
coya
Coya Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
Low
Report
Coya Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
1/21
09:59 am
coya
Coya Therapeutics, Inc. (NASDAQ: COYA) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $15.00 price target on the stock.
Medium
Report
Coya Therapeutics, Inc. (NASDAQ: COYA) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $15.00 price target on the stock.
1/21
08:44 am
coya
Coya Therapeutics Announces Pipeline Expansion - COYA 303: COYA 301 in Combination with GLP-1 Receptor Agonist for the Treatment of Inflammatory Diseases [Yahoo! Finance]
Medium
Report
Coya Therapeutics Announces Pipeline Expansion - COYA 303: COYA 301 in Combination with GLP-1 Receptor Agonist for the Treatment of Inflammatory Diseases [Yahoo! Finance]
1/21
08:15 am
coya
Coya Therapeutics Announces Pipeline Expansion - COYA 303: COYA 301 in Combination with GLP-1 Receptor Agonist for the Treatment of Inflammatory Diseases
Low
Report
Coya Therapeutics Announces Pipeline Expansion - COYA 303: COYA 301 in Combination with GLP-1 Receptor Agonist for the Treatment of Inflammatory Diseases